NRG-GY003. Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Esther Rehmus, MD
McDowell Cancer Research at 330-344-6348
Akron General Medical Center 1 Akron General Avenue (Formerly 400 Wabash Avenue) Akron, OH 44307 330-344-6000 1-800-221-4601 © 2016 Akron General Health System
This site complies with the HONcode standard for trustworthy health information: verify here.